Primary Peritoneal Cancer Therapeutics Market Size and Forecast 2026–2035
The global primary peritoneal cancer therapeutics market is estimated at USD 440 million in 2025 and is projected to reach approximately USD 915.3 million by 2035, expanding at a CAGR of 7.6% during 2026–2035.
The market is entering an important treatment transition. Surgery and platinum-based chemotherapy remain central to primary peritoneal cancer management, but the commercial mix is moving toward biomarker-selected targeted therapies, antibody-drug conjugates, PARP inhibitors, and immunotherapy.
Primary peritoneal cancer is a relatively rare malignancy that develops in the tissue lining the abdominal wall and abdominal organs. It shares biological and clinical characteristics with epithelial ovarian and fallopian-tube cancers and is generally staged and treated using the same therapeutic framework.
The National Cancer Institute continues to identify surgery followed by platinum-based chemotherapy as a principal treatment approach for advanced ovarian epithelial, fallopian-tube and primary peritoneal cancers. Treatment of recurrent disease can additionally involve cytotoxic chemotherapy, secondary cytoreductive surgery, hormonal treatment and targeted agents.
Market Definition
Primary peritoneal cancer is a malignancy that originates in the peritoneum-the thin tissue lining the abdominal wall and covering organs within the abdomen-and has not spread to the peritoneum from a cancer originating elsewhere. NCI notes that it is similar to epithelial ovarian cancer and is staged and treated in the same manner.
For market-sizing purposes, this report includes therapeutics and treatment procedures used specifically for primary peritoneal carcinoma, including systemic chemotherapy, targeted therapy, immunotherapy where indicated, maintenance treatment, cytoreductive surgery and selected intraperitoneal approaches.
The market excludes secondary peritoneal metastases originating from colorectal, gastric, pancreatic, appendiceal and other non-primary-peritoneal cancers. This distinction is important because therapeutic pathways and addressable commercial populations differ substantially.
White-Space Opportunity: Platinum-Resistant Primary Peritoneal Cancer
The largest near-term commercial white space is emerging in recurrent and platinum-resistant disease.
Historically, patients with ovarian, fallopian-tube and primary peritoneal cancers that progressed after platinum-based chemotherapy had relatively limited systemic treatment options.
In March 2024, the FDA granted full approval to mirvetuximab soravtansine-gynx (Elahere) for FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal cancer after one to three prior systemic regimens. In the MIRASOL study, which enrolled 453 patients, median overall survival reached 16.5 months with mirvetuximab versus 12.7 months with investigator's-choice chemotherapy.
The treatment's international commercial relevance widened further when the European Union authorized Elahere and NICE recommended it in June 2026 for eligible patients in England. NICE lists the UK price at £4,950 per 100-mg vial before confidential commercial discounts, illustrating the high revenue intensity associated with precision oncology therapies.
Two additional FDA decisions in early 2026 further widened this segment.
On February 10, 2026, pembrolizumab-based treatment was approved for PD-L1-positive platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal carcinoma after one or two prior systemic regimens. In KEYNOTE-B96, median overall survival among the PD-L1 CPS ≥1 population was 18.2 months with pembrolizumab-based therapy versus 14.0 months in the control group.
On March 25, 2026, the FDA approved relacorilant with nab-paclitaxel following the ROSELLA study. Median overall survival was 16.0 months versus 11.9 months with nab-paclitaxel alone, representing a 35% relative reduction in the risk of death.
These approvals create a larger commercial opportunity around biomarker testing, treatment sequencing and precision therapy in recurrent PPC.
Primary Peritoneal Cancer Therapeutics Market Strategic Insights
Targeted therapy is replacing chemotherapy as the principal source of market value even though platinum-taxane chemotherapy remains fundamental to first-line clinical management.
The related DataM Intelligence ovarian cancer drugs market already shows this transition: targeted therapies accounted for 65.7% of ovarian cancer drug revenue in 2024, reflecting the commercial importance of PARP inhibitors, antiangiogenic agents and newer antibody-drug conjugates.
Primary peritoneal cancer is likely to follow the same direction because it is commonly treated within the same clinical protocols and included alongside ovarian and fallopian-tube cancer in pivotal trials.
The market's next phase will be influenced by four factors: improved biomarker selection, a broader platinum-resistant treatment arsenal, increasing use of maintenance therapy and expansion of antibody-drug conjugates.
North America remains the revenue center, but Asia-Pacific represents the largest long-term volume opportunity. GLOBOCAN data indicate that Asia accounts for more than half of global five-year ovarian-cancer prevalence, providing a substantial adjacent patient pool for therapeutics used across ovarian, fallopian-tube and primary peritoneal malignancies.
Primary Peritoneal Cancer Therapeutics Market Trends
Antibody-drug conjugates are reshaping recurrent treatment
Antibody-drug conjugates are becoming one of the most commercially important innovations in gynecologic oncology.
Mirvetuximab established the first major commercial benchmark by targeting FRα-positive tumors. Its uptake has continued to build: AbbVie reported USD 182 million in global Elahere revenue during Q4 2025, up 22.6% year over year.
The pipeline is becoming more competitive.
In April 2026, GSK reported a 62% confirmed objective response rate with the B7-H4-targeted ADC mocertatug rezetecan in platinum-resistant ovarian cancer in the BEHOLD-1 study. GSK plans five pivotal Phase III studies, including studies in platinum-resistant and platinum-sensitive ovarian cancer settings.
These programs are relevant to the PPC market because advanced epithelial ovarian, fallopian-tube and primary peritoneal cancers are frequently evaluated within common clinical development programs.
Immunotherapy has entered the platinum-resistant market
Checkpoint inhibition historically produced mixed results across unselected ovarian-cancer populations. Biomarker selection is now changing that position.
The February 2026 FDA approval of pembrolizumab plus paclitaxel, with or without bevacizumab, established a PD-1-based regimen specifically for PD-L1-positive platinum-resistant epithelial ovarian, fallopian-tube and primary peritoneal carcinoma.
The European Commission approved the same pembrolizumab-based approach in April 2026, broadening its geographic commercial potential.
Biomarker testing is becoming part of treatment economics
BRCA1/2 mutation status, homologous recombination deficiency, folate receptor-alpha expression and PD-L1 expression increasingly determine which advanced treatments a patient may receive.
This changes the market from a therapy-only ecosystem into a combined diagnostic-treatment pathway.
Mirvetuximab requires FRα-positive disease. Pembrolizumab eligibility in its new platinum-resistant indication depends on PD-L1 CPS status. PARP inhibitors remain closely associated with BRCA and homologous-recombination biology.
As the number of biomarker-defined choices grows, companion diagnostics and coordinated pathology testing will play a larger role in oncology procurement and treatment sequencing.
Platinum resistance is becoming a distinct commercial segment
Platinum-based therapy remains the backbone of initial systemic treatment, but resistance creates the greatest unmet need.
This is where many of the newest high-value agents are entering the market: Elahere, pembrolizumab-based therapy, and relacorilant all address platinum-resistant populations under specific eligibility criteria.
Commercial competition is therefore shifting from broad treatment availability toward how effectively companies can position therapies within successive treatment lines.
HIPEC remains an important clinical research area
Hyperthermic intraperitoneal chemotherapy remains under investigation in selected advanced ovarian and primary peritoneal cancer settings rather than functioning as a universal standard for every PPC patient.
A recruiting Phase III GOG Foundation study is evaluating HIPEC with cisplatin during interval cytoreductive surgery followed by niraparib maintenance in HRD-positive stage III or IV ovarian, primary peritoneal and fallopian-tube cancers.
Further clinical evidence could influence the future share of surgery-associated and intraperitoneal treatment spending.
Primary Peritoneal Cancer Therapeutics Market Scope
| Metrics | Details |
| Historical Years | 2023–2024 |
| Base Year | 2025 |
| 2025 Market Size | USD 440 Million |
| Forecast Period | 2026–2035 |
| 2035 Market Size | USD 915.3 Million |
| CAGR | 7.6% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Treatment Types | Targeted Therapy, Chemotherapy, Surgery, Hormone Therapy, Radiation Therapy |
| End Users | Hospitals, Cancer Centers, Surgical Centers, Cancer Research Institutes, Others |
| North America | U.S., Canada, Mexico |
| Europe | Germany, UK, France, Italy, Spain, Rest of Europe |
| Asia-Pacific | China, Japan, India, Australia, South Korea, Rest of Asia-Pacific |
| Latin America | Brazil, Argentina, Rest of Latin America |
| Middle East & Africa | Saudi Arabia, UAE, South Africa, Israel, Türkiye, Rest of Middle East & Africa |
| Revenue Units | USD Million |
| Report Insights | Market Size, Forecast, Segment Share, Country Analysis, Pipeline, Biomarkers, Regulatory Developments, Competitive Landscape |
Primary Peritoneal Cancer Therapeutics Market Disruption Analysis
The market is undergoing a shift from largely uniform chemotherapy protocols toward increasingly differentiated precision-oncology pathways.
The earlier treatment model relied heavily on cytoreductive surgery followed by carboplatin and paclitaxel. These treatments remain essential, but recurrent disease increasingly leads patients into biomarker-driven pathways.
An FRα-positive patient may qualify for an antibody-drug conjugate. A PD-L1-positive patient may qualify for pembrolizumab-based therapy. BRCA or HRD status can affect maintenance strategies involving PARP inhibition.
Relacorilant adds a different mechanism because its FDA-approved platinum-resistant indication does not require biomarker selection.
This variety will make treatment sequencing increasingly important through 2035 and should support growth in both pharmaceutical revenue and diagnostic testing.
A second disruption is occurring in drug development. A Phase III study posted in July 2026 is evaluating SYS6043 against investigator's-choice chemotherapy in approximately 460 participants with platinum-resistant ovarian, primary peritoneal or fallopian-tube cancers.
The market is therefore likely to become more fragmented rather than being dominated by one therapeutic mechanism.
Primary Peritoneal Cancer Therapeutics Market Dynamics
Rising gynecologic cancer burden supports treatment demand
Primary peritoneal cancer is rare and is frequently grouped clinically with epithelial ovarian and fallopian-tube cancers.
Globally, there were approximately 324,603 new ovarian-cancer cases in 2022. DataM Intelligence's updated ovarian cancer drug analysis, citing IARC projections, places incidence at approximately 381,600 cases by 2030 and 447,500 by 2040.
The United States alone is expected to record approximately 21,010 new ovarian-cancer diagnoses in 2026, according to the American Cancer Society.
Because primary peritoneal carcinoma shares treatment pathways with epithelial ovarian disease, rising oncology treatment volumes support the addressable market for therapies approved across all three disease sites.
New approvals are increasing treatment value per patient
The market is growing not only because of patient volume but also because the value and complexity of therapy are increasing.
Maintenance treatments, ADCs, biologic therapies, immune checkpoint inhibitors and biomarker-driven treatment can generate significantly greater revenue per treated patient than older generic chemotherapy regimens.
NICE's listed price of £4,950 per 100-mg vial for mirvetuximab before negotiated discounts provides one illustration of the pricing associated with newer precision therapies.
High treatment cost remains a major restraint
The transition toward precision oncology also raises affordability concerns.
DataM Intelligence's ovarian-cancer drug analysis notes that advanced targeted treatments can impose a significant financial burden and cites research estimating an incremental cost of more than USD 33,000 for olaparib treatment in a Malaysian ovarian-cancer setting.
Access can therefore vary sharply across countries depending on reimbursement, insurance coverage, public health funding and availability of companion diagnostics.
Toxicity and treatment burden influence therapy selection
Cancer therapies differ materially in tolerability.
Cytotoxic chemotherapy may produce myelosuppression, neuropathy, nausea and other cumulative toxicities. ADCs and targeted treatments can introduce different adverse-event profiles.
For example, Elahere carries specific monitoring requirements for ocular toxicity, while relacorilant plus nab-paclitaxel is associated with hematologic and infectious adverse events requiring clinical management.
Safety profile, administration schedule, and supportive-care burden are therefore becoming meaningful competitive criteria.
Primary Peritoneal Cancer Therapeutics Market Segment Analysis
Targeted therapy leads with approximately 50.5% market share
Targeted therapy is estimated to account for 50.5% of the global primary peritoneal cancer therapeutics market in 2025, equivalent to approximately USD 222.2 million.
The segment includes PARP inhibitors, antiangiogenic therapies and antibody-drug conjugates used across eligible ovarian, fallopian-tube and primary peritoneal cancer populations.
Its dominant commercial share reflects high treatment costs, extended maintenance periods and the expanding role of precision oncology.
DataM Intelligence ovarian-cancer drug market, where targeted therapies accounted for 65.7% of drug revenue in 2024.
Chemotherapy retains a 31.2% share
Chemotherapy represents an estimated 31.2% of the market in 2025.
Platinum-taxane combinations remain an important foundation of treatment. Carboplatin and paclitaxel are extensively used in initial therapy, while recurrent disease can involve other agents including pegylated liposomal doxorubicin, gemcitabine, topotecan and taxanes depending on platinum sensitivity and previous treatment.
NCI continues to describe platinum-containing chemotherapy as a core component of therapy across ovarian epithelial, fallopian-tube and primary peritoneal cancers.
Chemotherapy's revenue share is expected to decline gradually as targeted drugs and immunotherapies capture more recurrent-disease spending, although absolute chemotherapy utilization will remain substantial.
Surgery accounts for approximately 14.5%
Surgery is estimated to account for 14.5% of the market in 2025.
Cytoreductive surgery aims to remove as much visible disease as possible. Clinical evidence has repeatedly linked complete or optimal cytoreduction with better outcomes in appropriately selected advanced gynecologic-cancer patients.
The segment also includes interval debulking approaches following neoadjuvant chemotherapy.
Hospitals dominate the end-user market
Hospitals are estimated to account for approximately 67.4% of 2025 market revenue, reflecting the complexity of systemic treatment, surgery, infusion management, imaging, biomarker assessment, and adverse-event monitoring.
Cancer centers account for an estimated 18.6%, surgical centers 9.8%, and research institutes and other settings approximately 4.2%.
Primary Peritoneal Cancer Therapeutics Market Regional Analysis
North America leads with 44.6% share
North America is estimated to account for approximately 44.6% of global primary peritoneal cancer therapeutics revenue in 2025, equivalent to about USD 196.2 million.
The region benefits from rapid adoption of high-value oncology therapies, extensive biomarker testing, specialist gynecologic-oncology networks, and comparatively early regulatory access.
The estimate is aligned with DataM Intelligence's broader ovarian-cancer drugs market, where North America accounted for 44.3% of global revenue in 2024.
United States Primary Peritoneal Cancer Therapeutics Market
The United States is estimated to represent approximately 38.1% of global PPC therapeutic revenue in 2025, equivalent to nearly USD 167.6 million.
Its leadership is reinforced by rapid regulatory adoption.
Between March 2024 and March 2026, the FDA approved or expanded three important treatment approaches covering eligible primary peritoneal cancer patients: mirvetuximab soravtansine, pembrolizumab-based therapy and relacorilant plus nab-paclitaxel.
The country's commercial advantage is likely to remain centered on precision therapy, molecular testing and earlier uptake of newly approved oncology products.
Europe Primary Peritoneal Cancer Therapeutics Market
Europe represents approximately 25.2% of global market revenue in 2025, equivalent to around USD 110.9 million.
Germany is modeled as the largest European country market at approximately 5.6% of global revenue, followed by the UK at 4.8% and France at 4.1%.
European growth is being supported by expansion of precision therapy access.
Elahere received EU marketing authorization in November 2024, and pembrolizumab-based treatment for eligible PD-L1-positive platinum-resistant ovarian, fallopian-tube and primary peritoneal carcinoma was approved in the European Union in April 2026.
United Kingdom Peritoneal Cancer Therapeutics Market
The UK accounts for an estimated 4.8% of global revenue, approximately USD 21.1 million in 2025.
The market gained an important new treatment pathway when NICE recommended mirvetuximab soravtansine in June 2026 for adults with FRα-positive, platinum-resistant high-grade serous epithelial ovarian, fallopian-tube or primary peritoneal cancer after one to three systemic treatment regimens.
Access through the NHS is likely to accelerate specialist use while establishing another international reimbursement benchmark for FRα-directed ADC therapy.
Asia-Pacific Primary Peritoneal Cancer Therapeutics Market
Asia-Pacific is estimated to account for 21.1% of global revenue in 2025, or approximately USD 92.8 million, and is projected to be the fastest-growing region through 2035.
Under the proposed market model, regional revenue approaches USD 250 million by 2035, increasing Asia-Pacific's global share to approximately 27%.
The growth opportunity is supported by the region's substantial gynecologic-cancer patient population. GLOBOCAN reports that Asia accounts for approximately 54.3% of global five-year ovarian-cancer prevalence.
China is estimated to contribute about 7.1% of global PPC therapeutic revenue in 2025, followed by Japan at 4.4% and India at approximately 3.3%.
China Peritoneal Cancer Therapeutics Market
China's PPC therapeutics market is estimated at approximately USD 31.2 million in 2025, or 7.1% of global revenue.
China's attractiveness comes from patient volume, expanding oncology infrastructure and increasing participation in global clinical development.
The pipeline also includes China-originated therapeutics. A Phase III trial posted in July 2026 is evaluating CSPC Megalith Biopharmaceutical's SYS6043 against chemotherapy in platinum-resistant ovarian, primary peritoneal and fallopian-tube cancer, with estimated enrollment of 460 participants.
India Peritoneal Cancer Therapeutics Market
India is estimated to represent approximately 3.3% of global revenue in 2025, equivalent to about USD 14.5 million.
Its revenue share remains smaller than its patient-volume potential because access to expensive targeted therapies varies substantially by payer, hospital and geography.
Growth should be supported by expanding oncology centers, molecular diagnostics, biosimilar availability and increased adoption of multidisciplinary cancer treatment.
Research into cytoreductive surgery and HIPEC also remains active in India and other Asia-Pacific markets.
Primary Peritoneal Cancer Therapeutics Competitive Landscape
The competitive landscape increasingly resembles the wider epithelial ovarian-cancer treatment market because primary peritoneal cancer patients are commonly included within shared indications and pivotal studies.
AbbVie has established an important position through Elahere, the FRα-directed ADC approved for eligible platinum-resistant ovarian, fallopian-tube and primary peritoneal cancer.
Merck & Co. strengthened its position in February 2026 when pembrolizumab became the first PD-1-based option approved in the U.S. for the specified PD-L1-positive platinum-resistant population.
AstraZeneca remains commercially relevant through Lynparza and the broader role of PARP inhibition in maintenance treatment.
GSK participates through Zejula and is building a next-generation ADC pipeline around mocertatug rezetecan.
Corcept Therapeutics became a notable new entrant following the March 2026 approval of Lifyorli in combination with nab-paclitaxel.
Roche/Genentech retains an established role through bevacizumab, which remains part of multiple first-line and recurrent ovarian/peritoneal cancer regimens. NCI summarizes phase III evidence showing improved progression-free survival in selected treatment settings when bevacizumab is added to chemotherapy.
Other companies relevant to the competitive and development landscape include Pfizer, Novartis, Amgen, Sanofi, CSPC Pharmaceutical Group and emerging oncology biotechnology companies developing ADCs and biomarker-directed therapies.
Company Positioning
Market Leaders: AbbVie, AstraZeneca, Merck, GSK and Roche combine established oncology portfolios, regulatory approvals and broad geographic commercialization.
High-Growth Challenger: Corcept Therapeutics has entered the gynecologic-oncology market with a differentiated mechanism through relacorilant.
Pipeline Innovators: GSK's B7-H4 program and CSPC's SYS6043 program illustrate the next wave of ADC competition.
The principal competitive question through 2035 will not simply be which company has an active drug. It will be where each therapy fits in the treatment sequence and how clearly a biomarker or clinical profile identifies the appropriate patient.
Recent Developments
- July 2026: A new Phase III study of SYS6043 versus investigator's-choice chemotherapy was posted for platinum-resistant advanced ovarian, primary peritoneal and fallopian-tube cancers, with approximately 460 participants planned.
- June 24, 2026: NICE recommended mirvetuximab soravtansine for eligible FRα-positive, platinum-resistant ovarian, fallopian-tube and primary peritoneal cancer.
- April 12, 2026: GSK reported a 62% confirmed objective response rate for mocertatug rezetecan in platinum-resistant ovarian cancer and announced plans for five pivotal Phase III studies.
- April 2, 2026: The European Commission approved pembrolizumab with paclitaxel, with or without bevacizumab, for eligible PD-L1-positive platinum-resistant disease.
- March 25, 2026: The FDA approved relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal cancer following the ROSELLA trial.
- February 10, 2026: The FDA approved pembrolizumab-based therapy for PD-L1-positive platinum-resistant epithelial ovarian, fallopian-tube and primary peritoneal carcinoma.
Procurement and Treatment Selection Criteria
For hospitals and cancer centers, therapeutic selection is becoming increasingly dependent on patient-specific characteristics rather than a single institutional formulary preference.
Key considerations include BRCA and HRD status, FRα expression, PD-L1 status, previous platinum response, prior bevacizumab use, previous lines of treatment and the patient's ability to tolerate expected toxicities.
Clinical efficacy remains the primary purchasing consideration, but drug acquisition cost, reimbursement, administration frequency, infusion-chair utilization, supportive-care requirements and companion-diagnostic availability increasingly influence real-world adoption.
For ADCs, oncology providers also assess target-expression requirements and toxicity-management infrastructure. For maintenance therapies, duration of treatment and adherence affect total cost of care.
Why Choose DataM Intelligence?
The report provides a dedicated commercial view of primary peritoneal cancer rather than combining the condition indiscriminately with all secondary peritoneal metastases.
It evaluates how new FDA and European approvals are changing the platinum-resistant treatment landscape and measures the commercial effect of targeted therapies, immunotherapy, chemotherapy and surgery.
Country-level analysis helps identify markets where patient volume, reimbursement and precision-oncology infrastructure create the strongest expansion opportunities.
Pipeline analysis tracks the next generation of antibody-drug conjugates and other therapies that could alter competitive positioning through 2035.
The report also assesses biomarkers, clinical development, treatment sequencing and procurement considerations relevant to manufacturers, healthcare providers, investors and licensing teams.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
